Summary
Background Actinic keratoses (AKs) are early in situ carcinomas of the skin caused by cumulative sun exposure. Cryosurgery is an easy and practicable lesion-directed approach for treatment of isolated lesions. Objectives To investigate whether an upfront combination of cryosurgery with a topical intervention is superior to cryosurgery alone for treatment of AK. Methods We performed a systematic literature search in MEDLINE, Embase and CENTRAL and hand searched pertinent trial registers for eligible randomized controlled trials until 17 July 2018. Results from individual studies were pooled using a random effects model. The risk of bias was estimated with the Cochrane Risk of Bias Tool and the quality of evidence of the outcomes with the GRADE approach. Results Out of 1758 records initially identified, nine studies with a total sample size of 1644 patients were included. Cryosurgery in combination with a topical approach showed significantly higher participant complete clearance rates than monotherapy [risk ratio (RR) 1Á74, 95% confidence interval (CI) 1Á25-2Á43, I 2 = 73%, eight studies]. The participant partial clearance rate was not statistically different (RR 1Á64, 95% CI 0Á88-3Á03, I 2 = 77%, three studies). The number of patients who completed the study protocol and did not withdraw due to adverse events was equal in both groups (RR 0Á98, 95% CI 0Á95-1Á01, I 2 = 75%, seven studies). The studies were estimated to have high risk for selective reporting bias.
Conclusions Our results suggest the superiority of a combination regimen for AK clearance, with equal tolerability. This study highlights the importance of a fielddirected approach in patients with multiple AKs or field cancerization.
What's already known about this topic?
• Cryosurgery is a fast and easy approach for treatment of isolated actinic keratoses.
• A variety of effective field-directed topical interventions are available, but they may lose efficacy in thicker lesions.
• Combining cryosurgery with a topical intervention offers the benefits of a lesionand field-directed approach.
What does this study add?
• This meta-analysis suggests the superiority of a combination of cryosurgery and topical interventions for participant complete clearance, without a difference in tolerability, in comparison with cryosurgery alone.
Actinic keratoses (AKs) are common lesions of the skin caused by long-term exposure to ultraviolet radiation. 1, 2 They can progress to cutaneous squamous cell carcinoma, although the risk is presumably low for single lesions. 3 However, if multiple AKs are present and if they are accompanied by signs of chronic actinic damage, the risk of malignant progression increases rapidly. 4, 5 Visible AK lesions may be surrounded by
tissue that clinically appears unaltered but bears significant ultraviolet-induced histological and genetic abnormalities. This concept has generally been accepted as field cancerization, although an exact clinical definition has not yet been coined. 6 As it is difficult to predict whether a lesion will become invasive cutaneous squamous cell carcinoma, international guidelines recommend early treatment of AK. 7, 8 Cryosurgery is a fast and easy approach to target single lesions in an officebased setting. The procedure usually involves liquid nitrogen and is applied in one to three freeze-thaw cycles. The advantage of this treatment is its ease of application and efficacy in hyperkeratotic lesions. 9 In patients with multiple lesions or field cancerization, topical interventions offer advantages as they are primarily field directed. A variety of agents for the treatment of AKs are available, with distinct mechanisms of action ranging from cytostatic effects to immune activation. The downsides are a longer duration of application and questionable efficacy in patients with thicker lesions, who are commonly excluded from larger trials.
In this context, we were interested to determine whether an upfront combination of cryosurgery followed by a topical intervention is more efficient than cryosurgery alone. We hypothesized that such a combination can combine the benefits of both a field-and lesion-directed approach. To address this question, we performed a systematic review with metaanalysis to summarize the current knowledge on the efficacy and safety of the combination of cryosurgery and topical intervention in comparison with cryosurgery monotherapy in patients with AKs.
Patients and methods

Protocol and registration
The protocol for this review was defined a priori and registered online in the PROSPERO international prospective register of systematic reviews (https://www.crd.york.ac.uk). The register ID was PROSPERO CRD42018102026. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 10 and the Cochrane Handbook For Systematic Reviews.
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Eligibility criteria
Patients with a clinical or histopathological diagnosis of AK were included. They were to be treated with a combination of cryosurgery and one of the following topical interventions: ingenol mebutate 0Á015% or 0Á05% gel, imiquimod 3Á75% or 5% cream, 5-fluorouracil 0Á5% or 5% cream, 5-fluorouracil 0Á5% plus salicylic acid 10% in solution, diclofenac 3% in 2Á5% hyaluronic acid, and photodynamic therapy with aminolaevulinic acid or its methyl ester. Cryosurgery as monotherapy served as the comparison. We included randomized control trials (RCTs) only in which the study participants (interindividual trials) or entire body parts (intraindividual trials) were investigated. Pseudorandomized trials, crossover trials, observational studies, retrospective studies and case series were excluded. Language restrictions were records in English or German.
Search strategy and data sources
We searched the electronic databases MEDLINE and Embase (both via Ovid) and the Cochrane Library CENTRAL to identify all relevant records until 10 July 2018 ( 
Study selection
Two authors (T.S. and M.V.H.) independently screened for eligibility the titles and abstracts that were identified in the electronic database searches. Trial registers were hand searched and assessed for eligibility by one author (T.S.). For records that were considered relevant according to title and abstract screening, full-text articles were obtained, and inclusion and exclusion criteria were applied by two review authors independently (T.S. and M.V.H.). Whenever discrepancies arose, resolution was achieved by discussion with a third independent author (C.B.).
Outcomes
The primary outcomes were (i) the participant complete clearance rate and (ii) the participant partial clearance rate, defined as the rate of participants who had all (100%) or ≥ 75% of their lesions cleared, respectively and (iii) the lesion-specific reduction, measured as a continuous outcome and defined as the proportion of cleared lesions after the end of treatment in comparison with baseline (change-from-baseline outcome according to the Cochrane Handbook for Systematic Reviews of Interventions). The secondary outcome was tolerability, defined as the number of participants who completed treatment according to the study protocol and did not discontinue due to treatment-related adverse events. All outcomes had to be reported at the earliest 2 months and not later than 6 months after the end of treatment.
Data collection, synthesis and management
Information for each included study regarding design, baseline characteristics, intervention, outcomes and risk of bias were collected and summarized by two authors independently (T.S. and M.V.H.) using Review Manager version 5Á3. 12 Wherever possible and suitable, we performed a meta-analysis of quantitative data using Review Manager. We used the random effects model, as clinical and methodological heterogeneity between the studies was likely. Dichotomous outcomes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs), and continuous outcomes as mean differences with 95% CIs. To address the influence of differences in the trial design on the effect estimate, we performed sensitivity analyses by repeating the meta-analysis with only interindividual trials. Where possible, we calculated the data following the intention-to-treat (ITT) principle. If meta-analysis for an outcome was impossible, we described the results qualitatively. Comparator-specific stratified analyses were performed if two or more trials were identified investigating the same comparisons of topical
PRISMA flowchart of the study. Selection process for study inclusion in the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).
interventions with cryosurgery. Subgroup analyses were performed to explore heterogeneity.
Assessment of risk of bias and quality of evidence
Two authors (M.V.H. and T.S.) independently assessed the risk of bias of the included studies with the Cochrane Risk of Bias Tool. 11 Discrepancies were thoroughly discussed and resolved with the full texts and supplementary material. The quality of evidence for each outcome was rated by the same authors using the software GRADEpro GDT (www.gradepro.org). 13 If at least 10 RCTs reported a specific comparison, we intended to assess publication bias by creating a funnel plot.
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Results
Study identification
Our literature search identified 1758 references. After title and abstract screening and removal of duplicates, 18 records underwent full-text review. Nine records were excluded, firstly because they did not investigate the interventions of interest (n = 3) [14] [15] [16] or did not report one of the predefined outcomes (n = 1). 17 Five more duplicates were additionally identified ( Fig. 1) . [18] [19] [20] [21] [22] Finally, nine RCTs with an overall sample size of 1644 met the eligibility criteria. Four of the nine studies investigated cryosurgery followed by imiquimod (3Á75% cream, n = 2; 23,24 5% cream, n = 2 25, 26 ) and two studies investigated cryosurgery followed by ingenol mebutate (0Á015% gel, n = 1; 27 0Á05% gel, n = 1
28
). The remaining three studies assessed diclofenac 3% in 2Á5% hyaluronic acid, 29 5-fluorouracil 0Á5% cream 30 and photodynamic therapy with aminolaevulinic acid after cryosurgery (Table S2) . 31 Six of the nine studies had an interindividual 24, 25, 27, [29] [30] [31] and three an intraindividual design. 23, 26, 28 All studies were conducted in North America: eight in the U.S.A. and one in Canada.
Bias assessment
The studies were at unclear risk for selection bias. Only four studies clearly described the generation of a random sequence for randomization. 24, 27, 29, 30 For the remaining five studies, it was unclear how randomization was achieved. 23, 25, 26, 28, 31 None of the included studies described whether allocation concealment was performed. Blinding of participants was not performed in five 23, 26, [28] [29] [30] of the nine included trials, which may result in performance bias for adverse events leading to discontinuation. Blinding of the outcome assessor was explicitly stated in seven trials. [24] [25] [26] [27] [28] 30, 31 Most studies were free of attrition bias. 23, 24, [26] [27] [28] 30 However, three studies had a dropout rate of > 10% without performing ITT analysis. 25, 29, 31 These studies were at high risk for attrition bias. We identified a high risk of selective reporting bias as the included studies often did not report all of the results for their predefined outcomes ( Fig. 2 and Fig. S1 ; see Supporting Information). [23] [24] [25] [26] [27] [28] [29] [30] [31] Subgroup analyses revealed that differences in the methodological quality were a relevant source of heterogeneity.
Outcomes
Eight studies were identified reporting participant complete clearance rates. [24] [25] [26] [27] [28] [29] [30] [31] Cryosurgery in combination with a topical approach showed significantly higher participant complete clearance rates than cryosurgery monotherapy (RR 1Á74, 95% CI 1Á25-2Á43, I 2 = 73%, eight studies) (Fig. 3a) . A sensitivity analysis with only interindividual trials revealed a similar effect size and degree of heterogeneity (RR 1Á68, 95% CI 1Á19-2Á35, I 2 = 77%, six studies). We rated the quality of evidence for this outcome as low due to the high risk of bias, high heterogeneity and imprecision (Table 1) . Information on the proportion of patients who had ≥ 75% of their baseline lesions cleared at the end of treatment was available from three studies. 27, 28, 30 Participants treated with a combination approach showed no significant difference regarding partial clearance rates compared with cryosurgery only (RR 1Á64, 95% CI 0Á88-3Á03, I 2 = 77%, three studies) (Fig. 3b) . A sensitivity analysis with only interindividual trials revealed a similar effect (RR 1Á31, 95% CI 0Á92-1Á87, I 2 = 59%, two studies). The quality of evidence was rated as very low because of the high risk of bias and high heterogeneity between the studies (Table 1) . Data on lesion-specific reduction were presented in eight of the nine studies. [23] [24] [25] [26] [27] [28] [29] [30] However, the results were inconsistently reported and did not allow us to pool the results or perform a meta-analysis. In general, more lesions were cleared with a combination treatment of cryosurgery and a topical intervention (range 73Á2-89%) in comparison with monotherapy with cryosurgery (range 39-76%) ( Table 2 ). The quality of evidence was rated as low due to the high risk of bias (Table 1) . Seven studies provided data on adverse events that led to discontinuation of treatment. [24] [25] [26] [27] [28] [29] [30] The number of patients who stopped treatment due to treatment-related adverse events was virtually equal in both groups (RR 0Á98, 95% CI 0Á95-1Á01, I 2 = 75%, seven studies) (Fig. 3c) . A sensitivity analysis excluding intraindividual trials revealed a similar effect (RR 0Á98, 95% CI 0Á94-1Á02, I 2 = 84%, five studies). The quality of evidence for this outcome was rated as very low as the studies showed a high risk of bias and high inconsistency ( Table 1) .
(c) 
Comparator-specific stratified analyses
Comparator-specific stratified analysis was possible for cryosurgery plus ingenol mebutate (two studies) 27, 28 and imiquimod (four studies). [23] [24] [25] [26] Cryosurgery followed by ingenol mebutate showed no significant differences regarding participant complete clearance rate (RR 3Á51, 95% CI 0Á22-56Á5, I 2 = 77, two studies) or partial clearance rate (RR 2Á97, 95% CI 0Á28-31Á0, I 2 = 83%, two studies) in comparison with cryosurgery alone. A sensitivity analysis was not performed as only two studies were available for this comparison. The lesionspecific reduction ranged from 82Á7% to 85Á1% for a combination of cryosurgery and ingenol mebutate ( Table 2 ). The number of patients who stopped treatment due to adverse events was equal in both groups (RR 0Á99, 95% CI 0Á97-1Á01, I 2 = 0%, two studies) ( Fig. S2 ; see Supporting Information). The quality of evidence was estimated as very low because of imprecision, high risk of bias and inconsistency (participant complete and partial clearance), and low due to a high risk of bias of the included studies (lesion-specific reduction, tolerability) (Table S3 ; see Supporting Information). The combination of cryosurgery with imiquimod revealed no significant difference of participant complete clearance in comparison with cryosurgery alone (RR 2Á46, 95% CI 0Á63-9Á57, I 2 = 87%, three studies). Sensitivity analysis with only interindividual trials showed similar results (RR 3Á11, 95% CI 0Á31-30Á9, I 2 = 94%, two studies). The lesion-specific reduction ranged from 73Á2% to 79Á3% for the combination therapy (Table 2) . Tolerability in terms of adverse events leading to discontinuation was similarly distributed in both groups (RR 0Á99, 95% CI 0Á97-1Á01, I 2 = 0%, three studies; interindividual trials only: RR 0Á99, 95% CI 0Á97-1Á01, I 2 = 0%, two studies) ( Fig. S3 ; see Supporting Information). The quality of evidence was graded as very low (participant complete clearance) due to imprecision, high risk of bias and inconsistency, and low because of a high risk of bias (lesion- 25 had a high risk for selective reporting, mostly because they did not report the outcomes that they had described in the methods part (À2 from the GRADE score). 29 Hashim 2016, 28 Hoover 2014 30 and NCT00774787 26 had a high risk of performance bias as participants were not blinded. The outcome assessor was not blinded in the study Berlin 2008 . 29 Regarding attrition bias, two studies (Berlin 2008  29 and Tan 2007) 25 demonstrated a high risk, mostly because they did not perform an intention-to-treat analysis. The risk of selective reporting remains unclear in the study Hoover 2014. 30 Five further studies (Berlin 2008 , 29 Hashim 2016, 28 Jorizzo 2010, 24 NCT0774787 26 and Tan 2007) 25 had a high risk of selective reporting, mostly because they did not report the outcomes that they had described in the methods part (À2).
specific reduction, tolerability) (Table S4 ; see Supporting Information). The participant partial clearance was not consistently reported for this subgroup.
Discussion
In this study we addressed the question of whether a combination approach of cryosurgery plus a topical agent is preferable to cryosurgery alone in patients with AK. Our results revealed the superiority of the combination regarding the outcome participant complete clearance. Statistical analysis showed a significant difference only for complete clearance but not for partial clearance. This may be explained by the fact that the results from only three studies were pooled for the latter outcome, whereas eight trials provided data on participant complete clearance rates. Thus, the estimate for partial clearance may be underpowered. A quantitative synthesis for lesion-specific reduction was not possible, as data were reported insufficiently and measures of dispersion were lacking. Furthermore, pooling lesion-specific values is not without problems from a methodological point of view, because it is not the individual lesions that are randomized but the patients or entire treatment areas that represent the basis for sample-size calculations. Thus, we decided to describe the lesion-specific reduction qualitatively. Consistently with the participant-specific efficacy results, the lesion-specific reduction was consistently higher for the combination compared with cryosurgery alone, ranging from 73Á2% to 89% and from 39% to 76%, respectively. The efficacy for cryosurgery as monotherapy in our analysis was largely concordant with values reported in other RCTs. [32] [33] [34] [35] Krawtchenko et al. reported a participant complete clearance rate of 68% of patients treated with cryosurgery, which dropped to 28% at the 12-month follow-up. 34 As we included only efficacy data obtained 2-6 months after the end of treatment, conclusions on the long-term efficacy of the combination of cryosurgery with a topical agent were not possible. Kaufmann et al. found a high lesion-specific response rate of 88% for AKs located on the extremities that had been treated with cryosurgery only. 33 This contrasts with our observations.
Lesions of the limbs are considered difficult to treat, and efficacy results are usually worse for this localization compared with the face or scalp. Three trials in our analysis included AK on the dorsal hands, revealing rather low clearance rates ranging from 39% to 68%. 23, 28, 29 This underlines that cryosurgery alone may not be sufficient for sustained lesion clearance and that a combination with topical treatment is preferable here. Zane et al. provided evidence that cryosurgery alone is a highly effective treatment for patients with isolated AK (maximum four lesions) on the face and scalp. 9 In contrast, the baseline AK count in the trials included in our data analysis ranged from 4Á6 28 to 12 30 lesions. Hence, we propose that the results are only generalizable to patients with multiple AKs or field cancerization. In cases of single and well-defined lesions, cryosurgery alone remains an effective and practicable approach for both patients and physicians, and adding a topical intervention may not be necessary. In patients with multiple lesions within a larger field with signs of chronic exposure to ultraviolet radiation, subclinical changes are likely to be present adjacent to clinically visible lesions. Here, adding a topical intervention after treating thicker and hyperkeratotic AKs with cryosurgery represents an attractive and tolerable approach to target both visible AKs and the entire actinically damaged field. The tolerability of the interventions of interest was measured by the number of patients who successfully completed the study protocol and did not withdraw due to treatmentrelated adverse events. This outcome was applied in several treatment guidelines and meta-analyses to estimate the tolerability and feasibility of interventions for AKs. 7, 8 Although there were more patients who discontinued the treatment in the combination group compared with monotherapy, this difference was not statistically significant and the size of the effect was negligible. One exception is the study conducted by Berlin and Rigel, which reported a high dropout rate of patients treated with cryosurgery followed by diclofenac sodium. 29 It is conceivable that the attrition was due to compliance issues, as diclofenac sodium should be applied twice daily over 90 days, and not explained by treatment-related serious adverse events. Altogether, our analyses suggest that a combination is equally tolerable compared with cryosurgery alone in all subgroups that were analysed by us. A major limitation of this study is the inclusion of only RCTs and the high clinical and methodological heterogeneity of the interventions. Firstly, the performance of cryosurgery was little standardized throughout all of the studies, and distinct freeze-thaw cycles and freezing times were used. Secondly, a variety of topical agents were used with distinct mechanisms of action and durations of application. Two of the included trials applied the topical interventions in an offlabel use as the treatment field was larger than recommended in the summary of product characteristics. 25, 28 Furthermore, the size of the treatment areas varied. Some studies investigated an area of 25 cm 2 , which is regarded as a small or limited field and may not represent a full field-directed approach. 27 This limitation should be kept in mind when generalizing our results to other populations. Subgroup analysis was possible for the topical agents ingenol mebutate and imiquimod. In both groups, the participantspecific clearance rates of the combination were superior to those of monotherapy with cryosurgery, yet without statistical significance. The effect size for both agents was consistent and similar to the overall analysis. Thus, the lack of significance may be explained by a small sample size and a lack of power. Further important limitations are the language restriction to records published in English or German and the fact that inter-and intraindividual trials were analysed together. A proper adjustment of the standard errors was not possible because cluster correlations and design effects were not reported in the primary intraindividual studies. To address this effect, we performed sensitivity analysis after exclusion of intraindividual trials for each outcome, revealing results comparable with those achieved with all studies. Nevertheless, we cannot exclude that the CIs of our pooled results are artificially narrow and may not reflect the true variability.
Taking the evidence together, this review suggests that a combination of cryosurgery with a topical intervention may be more effective than cryosurgery alone in patients with multiple AKs and field cancerization. Our results underline that cryosurgery alone may not be sufficient to achieve disease control in difficult-to-treat lesions. Furthermore, they highlight the importance of a field-directed approach in patients with multiple AKs.
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